


# 2019 Mesothelioma Meeting

JULY 10-12, 2019  
NEW YORK, NEW YORK

## Venue information

Westin New York at Times Square  
270 W. 43rd Street  
New York, NY, USA 10036

**Majestic Ballroom**



## Wifi Information

Network Information: WestinMeetingRooms

Password: meso19

Sponsored by:  Bristol-Myers Squibb

## Registration, Majestic Ballroom Foyer


**Wednesday, July 10 14:00 - 19:00**


**Thursday, July 11 07:00 - 16:30**

**Friday, July 12 07:00 - 15:00**

**Nursing Room Location: Triad Room, 12th Floor**

### 5th Floor





# 2019 Mesothelioma Meeting

JULY 10-12, 2019  
NEW YORK, NEW YORK

**WESTIN NEW YORK AT TIMES SQUARE, NEW YORK, NEW YORK**

Sponsored by the IASLC, July 10-12, 2019

Co-chairs: Michele Carbone, MD PhD | Harvey Pass, MD | Raphael Bueno, MD | Anne Tsao, MD

## WEDNESDAY JULY 10, 2019

Time	Event/Session
14:00 – 19:00	Registration Opening
18:30 – 19:00	<b>RECEPTION</b>
19:00 – 20:00	<b>KEYNOTE LECTURE</b> Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States
20:00 – 20:15	Q & A

## THURSDAY JULY 11, 2019

Time	Event/Session
07:00 – 16:30	Registration Opening Hours
07:30 – 07:45	<b>WELCOME</b>
07:45 – 08:50	<b>FGFR/PDGFR/ANGIOGENESIS SESSION</b> Chairs: Mary Hesdorffer, Mesothelioma Applied Research Foundation, United States & Giorgio Scagliotti, University of Torino, Italy
07:45 – 07:50	<b>Bevacizumab MAPS I</b> Gerard Zalcman, Bichat University Hospital, France
07:50 – 07:55	<b>LUME-Meso Nintedanib</b> Giorgio Scagliotti, University Of Torino, Italy
07:55 – 08:00	<b>S0905 Cediranib</b> Anne Tsao, United States
08:00 – 08:05	<b>Nintedanib Salvage</b> Antoinette Wozniak, UPMC Hillman Cancer Center, United States
08:05 – 08:10	<b>Nintedanib Maintenance</b> Sanjay Popat, The Royal Marsden, United States
08:10 – 08:15	<b>Imatinib Mesylate</b> Tom Stinchcombe, Duke Cancer Institute, United States
08:15 – 08:20	<b>Carotuximab (TRC105)</b> Melina Marmarelis, University Of Pennsylvania, United States
08:20 – 08:25	<b>FGFR Inhibitors (Pemigatinib)</b> Matt Gubens, University Of California San Francisco, United States
08:25 – 08:30	<b>NGR019 (NGR-hTNF)</b> Diego Cortinovis, San Gerardo Hospital, Italy

## THURSDAY JULY 11, 2019

Time	Event/Session
08:30 – 08:35	<b>Bevacizumab-Atezolizumab</b> Anne Tsao, M.D. Anderson Cancer Center, United States
08:35 – 08:40	<b>Nintedanib-Pembrolizumab</b> Arnaud Scherpereel, Hospital of the University (CHRU) of Lille, France
08:40 – 08:45	<b>(BEAT) Carbo-pem-bev-atezo</b> Sanjay Popat, The Royal Marsden, United States
08:45 – 09:00	<b>DISCUSSION</b>
09:00 – 10:05	<b>IMMUNE CHECKPOINT INHIBITORS AS SINGLE AGENTS</b> Chairs: Bruce Robinson, UWA School of Medicine, Australia & Tom Stinchcombe, Duke Cancer Institute, United States
09:00 – 09:10	<b>Science of Checkpoint Inhibitors</b> Paul Baas, Netherlands Cancer Institute, Netherlands
09:10 – 09:15	<b>Pembrolizumab</b> Corey Langer, University Of Pennsylvania, United States
09:15 – 09:20	<b>Nivolumab</b> Matthew Gubens, University Of California San Francisco, United States
09:20 – 09:25	<b>Nivolumab-Japan MERIT Trial</b> Yasushi Goto, National Cancer Center Hospital, Japan
09:25 – 09:30	<b>Atezolizumab</b> Aaron Mansfield, Mayo Clinic, United States
09:30 – 09:35	<b>Durvalumab</b> Anna Nowak, University Of Western Australia, Australia
09:35 – 09:40	<b>Avelumab</b> Melina Marmarelis, University Of Pennsylvania, United States
09:40 – 09:45	<b>Tremelimumab</b> Luana Calabrò, Center For Immuno-oncology, University Hospital of Siena, Italy
09:45 – 10:05	<b>DISCUSSION</b>
10:05- 10:35	<b>DEBATE 1: PDL1 TUMOR MUTATION BURDEN TESTING BEFORE IMMUNOTHERAPY</b> Moderator: Fred Hirsch, Mount Sinai Health System, United States
10:05 – 10:20	<b>DEBATE 1: PDL1 Testing and Tumor Mutation Burden Testing SHOULD be Done Before Selecting Immunotherapy in MPM</b> Paul Baas, Netherlands Cancer Institute, Netherlands
10:20 – 10:35	<b>DEBATE 1: PDL1 Testing and Tumor Mutation Burden Testing should NOT be Done Before Selecting Immunotherapy in MPM</b> Aaron Mansfield, Mayo Clinic, United States
10:35 – 10:45	<b>BREAK</b>
10:45 – 11:35	<b>RADIATION</b> Chairs: Joel Neal, Stanford University, United States & Boris Sepesi, The University Of Texas M.d. Anderson Cancer Center, United States
10:45 – 10:55	<b>New Developments in XRT: NCI-IASLC-MARF Radiation Guidelines</b> Andreas Rimner, Memorial Sloan Kettering Cancer Center, United States
10:55 – 11:00	<b>SMART Neoadjuvant Therapy</b> Marc de Perrot, Princess Margaret Cancer Centre, Canada

## THURSDAY JULY 11, 2019

Time	Event/Session
11:00 – 11:05	<b>XRT Adjuvant Pembrolizumab</b> Daniel Gomez, Memorial Sloan Kettering Cancer Care, United States
11:05 – 11:10	<b>Tumor Treating Fields</b> Giovanni Luca Ceresoli, Humanitas Gavazzeni, Bergamo, Italy
11:10 – 11:15	<b>IMRT Canada</b> Marc de Perrot, Princess Margaret Cancer Centre, Canada
11:15 – 11:20	<b>Accelerated Hypofractionated XRT</b> Saumil Gandhi, M.D. Anderson Cancer Center, United States
11:20 – 11:35	<b>DISCUSSION</b>
11:35 – 12:25	<b>DNA REPAIR SESSION</b> Chairs: Michele Carbone, University Of Hawaii Cancer Center, United States & Isabelle Opitz, University Hospital Zurich, Switzerland
11:35 – 11:45	<b>Science</b> Dean Fennell, University of Leicester & University Hospitals of Leicester, UK
11:45 – 11:50	<b>CDK4/6 Abemaciclib</b> Ibiayi Dagogo-Jack, Massachusetts General Hospital, United States
11:50 – 11:55	<b>PARP Inhibitors</b> Raffit Hassan, National Cancer Institute, United States
11:55 – 12:00	<b>Aurora Kinase Inhibitor (alisertib)</b> Anne Tsao, M.D. Anderson Cancer Center, United States
12:00 – 12:05	<b>Wee1</b> Ravi Salgia, City of Hope, United States
12:05 – 12:10	<b>TRC102</b> Joel Neal, Stanford University, United States
12:10 – 12:25	<b>DISCUSSION</b>
12:25 – 13:55	<b>LUNCH</b>
12:45 – 13:45	<b>NOVOCURE SYMPOSIUM: BREAKING NEW GROUND IN MALIGNANT PLEURAL MESOTHELIOMA</b> Charles Simone – New York Proton Center, Matthew Ballo- West Cancer Center & Research Institute, Giovanni Ceresoli- Cliniche Humanitas Gavazzeni <b>novocure™</b>
13:55 – 14:25	<b>ANTI-METABOLITES AND CHEMOTHERAPY</b> Chairs: Giovanni Luca Ceresoli, Humanitas Gavazzeni, Bergamo, Italy & Gerard Zalcman, Bichat University Hospital, Aphp, France
13:55 – 14:05	<b>Science of Arginine Deprivation</b> Peter Szlosarek, Barts Cancer Center, UK
14:05 – 14:10	<b>ADI-PEG20 + Atezolizumab</b> Peter Szlosarek, Barts Cancer Center, UK
14:10 – 14:15	<b>Maintenance Pemetrexed</b> Arkadiusz Dudek, HealthPartners, United States
14:15 – 14:25	<b>DISCUSSION</b>

## THURSDAY JULY 11, 2019

Time	Event/Session
14:25 – 15:40	<b>MISCELLANEOUS SESSION</b> Chairs: Joachim Aerts, Erasmus Mc, Netherlands & Arnaud Scherpereel, Hospital of the University (CHRU) of Lille, France
14:25 – 14:30	<b>Brentuximab</b> Anne Tsao, M.D. Anderson Cancer Center, United States
14:30 – 14:35	<b>Tazemetostat</b> Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States
14:35 – 14:40	<b>Napabucasin (BBI608)</b> TBD
14:40 – 14:45	<b>Cullen Neddylation Inhibitor (Pevonedistat – MLN4924, TAK924)</b> Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States
14:45 – 14:50	<b>343EphB4 &amp; Recombinant EphB4-has</b> Ravi Salgia, City of Hope, United States
14:50 – 14:55	<b>Glutaminase Inhibitor CB-839</b> Aaron Lisberg, University Of California, Los Angeles, United States
14:55 – 15:00	<b>Fus-1 Nanoparticles</b> Ibiayi Dagogo-Jack, Massachusetts General Hospital, United States
15:00 – 15:05	<b>Trabectedin (ATREUS trial, NCT 02194231) P</b> Diego Cortinovis, San Gerardo Hospital, Italy
15:05 – 15:10	<b>Lurbinectedin</b> Joachim Aerts, Erasmus Mc, Netherlands
15:10 – 15:15	<b>YS110 (CD26)</b> Joachim Aerts, Erasmus Mc, Netherlands
15:15 – 15:20	<b>Ganetespib</b> Dean Fennell, University Of Leicester & University Hospitals Of Leicester, UK
15:20 – 15:25	<b>FAK Inhibitors</b> Dean Fennell, University Of Leicester & University Hospitals Of Leicester, UK
15:25 – 15:30	<b>Defactinib + Pembrolizumab</b> TBD
15:30 – 15:40	<b>DISCUSSION</b>
15:40 – 16:10	<b>DEBATE 2: GENOMIC PROFILING</b> Moderator: Michele Carbone, University Of Hawaii Cancer Center, United States
15:40 – 16:10	<b>DEBATE 2: Genomic Profiling SHOULD be SOC in MM</b> Raphael Bueno, Brigham And Women's Hospital, United States
15:40 – 16:10	<b>DEBATE 2: Genomic Profiling Should NOT be SOC in MM</b> Isabelle Opitz, University Hospital Zurich, Switzerland
16:10 – 16:25	<b>BREAK</b>
16:25 – 17:40	<b>MESOTHELIN-TARGETING AGENTS</b> Chairs: Natasha Leighl, Princess Margaret Cancer Centre, Canada & Anna Nowak, University Of Western Australia, Australia
16:25 – 16:35	<b>Science</b> Raffit Hassan, National Cancer Institute, United States

## THURSDAY JULY 11, 2019

Time	Event/Session
16:35 – 16:40	<b>Amatuximab</b> Hedy Lee Kindler, University Of Chicago, United States
16:40 – 16:45	<b>ARTEMIS (Chemo-Amatuximab)</b> Hedy Lee Kindler, University Of Chicago, United States
16:45 – 16:50	<b>Anetumab Ravtansine</b> Hedy Lee Kindler, University Of Chicago, United States
16:50 – 16:55	<b>Listeria Mesothelin Vaccine CRS-207</b> Matthew Gubens, University Of California San Francisco, United States
16:55 – 17:00	<b>CRS207 + CHEMOTHERAPY</b> Antoinette Wozniak, UPMC Hillman Cancer Center, United States
17:00 – 17:05	<b>SS1P</b> Giovanni Luca Ceresoli, Humanitas Gavazzeni, Bergamo, Italy
17:05 – 17:10	<b>LMB-100</b> Raffit Hassan, National Cancer Institute, United States
17:10 – 17:15	<b>BMS-986148 (ADC)</b> Aaron Mansfield, Mayo Clinic, United States
17:15 – 17:35	<b>DISCUSSION</b>
17:35 – 18:05	<b>MET SESSION</b> Chairs: Patrick Forde, Johns Hopkins University, United States & Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States
17:35 – 17:45	<b>Science</b> Ravi Salgia, City of Hope, United States
17:45 – 17:50	<b>MET TKIs and ADCs</b> Ibiayi Dagogo-Jack, Massachusetts General Hospital, United States
17:50 – 17:55	<b>Capmatinib (INC 280)</b> Melina Marmarelis, University Of Pennsylvania, United States
17:55 – 18:00	<b>Cabozantinib</b> Joel Neal, Stanford University, United States
18:00 – 18:05	<b>DISCUSSION</b>

## FRIDAY JULY 12, 2019

Time	Event/Session
07:00 – 15:00	Registration Opening Hours
08:00 – 08:10	<b>WELCOME</b>
08:10 – 09:30	<b>SURGICALLY RESECTABLE SESSION</b> Chairs: Marc de Perrot, Princess Margaret Cancer Centre, Canada & David Harpole, Duke University, United States
08:10 – 08:20	<b>NCI-IASLC-MARF Surgical Guidelines</b> Joseph Friedberg, University Of Maryland School Of Medicine, United States
08:20 – 08:25	<b>EPP vs no EPP</b> Jay Lee, UCLA Health, UCLA Health, United States

## FRIDAY JULY 12, 2019

Time	Event/Session
08:25 – 08:30	<b>P/D vs no P/D</b> Harvey Pass, NYU Langone Medical Center, United States
08:30 – 08:35	<b>EORTC P/D-Chemo vs. Chemo-P/D</b> Paul Baas, Netherlands Cancer Institute, Netherlands
08:35 – 08:40	<b>Neoadjuvant Dasatini</b> Boris Sepesi, The University Of Texas M.d. Anderson Cancer Center, United States
08:40 – 08:45	<b>Neoadjuvant Pembrolizumab</b> Jay Lee, United States
08:45 – 08:50	<b>Neoadjuvant Nivolumab/Ipilimumab -Nivolumab</b> Patrick Forde, Johns Hopkins University, United States
08:50 – 08:55	<b>Neoadjuvant Durvalumab-Tremelimumab</b> TBD
08:55 – 09:00	<b>S1619 (Chemo-Atezolizumab)</b> Anne Tsao, M.D. Anderson Cancer Center, United States
09:00 – 09:05	<b>Surgical QOL Assessments</b> Mary Hesdorffer, Mesothelioma Applied Research Foundation, United States
09:05 – 09:15	<b>Translational Correlates in I/O trials</b> Boris Sepesi, The University Of Texas M.d. Anderson Cancer Center, United States
09:15 – 09:30	<b>DISCUSSION</b>
09:30 – 10:00	<b>DEBATE 3: NEOADJUVANT CHEMOTHERAPY VS. NO NEOADJUVANT THERAPY</b> Moderator: Joseph Friedberg, University Of Maryland School Of Medicine, United States
09:30 – 09:45	<b>Debate 3: Neoadjuvant Chemotherapy vs. No Neoadjuvant Therapy – CON</b> David Harpole, Duke University, United States
09:45 – 10:00	<b>Debate 3: Neoadjuvant Chemotherapy vs. No Neoadjuvant Therapy – PRO</b> Harvey Pass, NYU Langone Medical Center, United States
10:00 – 10:15	<b>BREAK</b>
10:15 – 12:00	<b>IMMUNE CHECKPOINT INHIBITORS + CHEMO OR OTHER IMMUNE COMBINATION CO-STIMULATORY AND CO-INHIBITOR MOLECULES</b> Chairs: Dean Fennell, UK & Anne Tsao, United States
10:15 – 10:25	<b>Science of Combinations</b> Anna Nowak, University Of Western Australia, Australia
10:25 – 10:30	<b>DREAM Australia</b> Anna Nowak, University Of Western Australia, Australia
10:30 – 10:35	<b>PrE0505 Chemo + Durvalumab</b> Patrick Forde, Johns Hopkins University, United States
10:35 – 10:40	<b>Pembrolizumab + Chemo (Canada)</b> Natasha Leighl, Princess Margaret Cancer Centre, Canada
10:40 – 10:45	<b>Durvalumab + Tremelimumab</b> TBD
10:45 – 10:50	<b>PROMISE-mesoETOP</b> Sanjay Papat, The Royal Marsden, United States
10:50 – 10:55	<b>Ipilimumab -Nivolumab vs Chemo Frontline</b> Arnaud Scherpereel, Hospital of the University (CHRU) of Lille, France



## FRIDAY JULY 12, 2019

Time	Event/Session
10:55 – 11:00	<b>INITIATE</b> Paul Baas, Netherlands Cancer Institute, Netherlands
11:00 – 11:05	<b>NIBIT-MESO</b> Luana Calabro, Center For Immuno-onology, University Hospital of Siena, Italy
11:05 – 11:10	<b>MAPS 2</b> Arnaud Scherpereel, Hospital of the University (CHRU) of Lille, France
11:10 – 11:15	<b>LAG525 + Spatalizumab</b> Tom Stinchcombe, Duke Cancer Institute, United States
11:15 – 11:20	<b>INDUCE-1 GDK3359609 (ICOS) + I/O</b> Melissa Johnson, Sarah Cannon Research Institute, United States
11:20 – 11:25	<b>Arginine Inhibitor + I/O</b> Melissa Johnson, Sarah Cannon Research Institute, United States
11:25 – 11:30	<b>Pembrolizumab + CRS207</b> Aaron Mansfield, Mayo Clinic, United States
11:30 – 11:35	<b>Pembrolizumab + Anetumab</b> Aaron Mansfield, Mayo Clinic, United States
11:35 – 11:40	<b>B7H3 Inhibition + I/O</b> Corey Langer, University Of Pennsylvania, United States
11:40 – 11:45	<b>CSF-1R+ I/O Therapy</b> Jeremy Cetnar
11:45 – 12:00	<b>DISCUSSION</b>
12:00 – 12:30	<b>PANEL: NCI CTEP/FDA/ADVOCATE PANEL – MESOTHELIOMA RESEARCH, MASTER PROTOCOLS UK, USA</b> Panel: Wolf Lindwasser, USA; Dean Fennell, UK; Mary Hesdorffer, USA; Shakun Malik, USA; Anne Tsao, USA; Gideon Blumenthal, USA
12:30 – 14:00	<b>LUNCH</b>
14:00 – 14:30	<b>MTOR/PI3K/AKT</b> Chairs: Aaron Mansfield, United States & Antoinette Wozniak, United States
14:00 – 14:10	<b>Science</b> Marjorie Zauderer, United States
14:10 – 14:15	<b>Everolimus</b> Marjorie Zauderer, United States
14:15 – 14:20	<b>GDC0980 (mTOR/PI3K)</b> Aaron Mansfield, United States
14:20 – 14:30	<b>DISCUSSION</b>
14:30 – 15:25	<b>T CELL THERAPIES</b> Chairs: Melissa Johnson, Sarah Cannon Research Institute, United States & Harvey Pass, NYU Langone Medical Center, United States
14:30 – 14:40	<b>Science</b> Bruce Robinson, UWA School of Medicine, Australia
14:40 – 14:45	<b>Autologous T Cells – Mesothelin</b> Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, United States
14:45 – 14:50	<b>CAR T-Mesothelin</b> Andy Haas, University of Pennsylvania, United States



## FRIDAY JULY 12, 2019

Time	Event/Session
14:50 – 14:55	<b>Hu-CART Meso NCT03054298</b> Andy Haas, University of Pennsylvania, United States
14:55 – 15:00	<b>Autologous Redirected RNA Meso-CIR T Cells</b> Andy Haas, University of Pennsylvania, United States
15:00 – 15:05	<b>Preclinical Dendritic Cell Therapy</b> Joachim Aerts, Erasmus Mc, Netherlands
15:05 – 15:10	<b>Clinical Dendritic Cell Therapy</b> Joachim Aerts, Erasmus Mc, Netherlands
15:10 – 15:25	<b>DISCUSSION</b>
15:25 – 16:45	<b>VACCINES AND INTRAPLEURAL, GENE THERAPY</b> Chairs: Shakun Malik, NCI, United States & Boris Sepesi, Anderson United States
15:25 – 15:35	<b>Science</b> Daniel Serman, Nyu Langone Health, United States
15:35 – 15:40	<b>GL-ONC1</b> Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States
15:40 – 15:45	<b>rAd-IFN</b> Daniel Serman, Nyu Langone Health, United States
15:45 – 15:50	<b>IFN-<math>\beta</math> HSV-Thymidine Kinase Adenoviral Vectors</b> Andy Haas, University of Pennsylvania, United States
15:50 – 15:55	<b>AdV-tk</b> Daniel Serman, Nyu Langone Health, United States
15:55 – 16:00	<b>ONCOS-102</b> Christian Rolfo, University Of Maryland Greenebaum Comprehensive Cancer Center, United States
16:00 – 16:05	<b>CRS-207</b> Christian Rolfo, University Of Maryland Greenebaum Comprehensive Cancer Center, United States
16:05 – 16:10	<b>WT-1 Vaccine Adjuvant</b> Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, United States
16:10 – 16:15	<b>Intracavitary Cisplatin</b> Raphael Bueno, Brigham And Women's Hospital, United States
16:15 – 16:20	<b>Hyperthermic Intrapleural Chemo</b> Raphael Bueno, Brigham And Women's Hospital, United States
16:20 – 16:25	<b>Intrapleural Cryotherapy</b> Erin Gillaspie, Vanderbilt University Medical Center, United States
16:25 – 16:30	<b>Intrapleural PDT</b> Keith Cengel, University Of Pennsylvania, United States
16:30 – 16:45	<b>DISCUSSION</b>
16:45 – 17:00	<b>CLOSING</b>